Endonovo Therapeutics Inc (ENDV)

[Biotech_Tradez]

Common equity holders are last in line to get their money in an acquisition, so if that is your only vehicle for making a profit on this stock then you are taking a very big gamble.

First, you have no clue what the acquisition price would be nor how Long from now it would come, so you have the time value of money and you have a business that only gets funding via dilutive convertible debt.

Secondly, you have no clue how the convertible debt holders are going to act in an acquisition, i.e. do they get bought out with their interest and their conversion premiums (35-50% in some cases) or if they are going to convert into common at a huge discount before it is announced and dilute out the common equity holders. Technically the Whelans' are insiders so they would have to convert after but with pink sheet companies you really have no rules and they have already had issues with the regulators over their conduct with convertible notes.

Second, you have to understand that ENDV is cheaper if that company wants to acquire this type of tech, you are also making the big assumption that they want to acquire it.